SK Biopharm targets $311 mn for Cenobamate US sales
It aims to top the prescription drug sector by increasing local TRx of the epilepsy drug to over 30,000
By Feb 16, 2024 (Gmt+09:00)
Samsung steps up AR race with advanced microdisplay for smart glasses


When in S. Korea, it’s a ritual: Foreigners make stops at CU, GS25, 7-Eleven


Maybe Happy Ending: A robot love story that rewrote Broadway playbook


NPS yet to schedule external manager selection; PE firms’ fundraising woes deepen


US auto parts tariffs take effect; Korea avoids heavy hit



South Korea's SK Biopharmaceuticals targeted 416 billion won ($311 million) for its epilepsy treatment Cenobamate in the US market this year.
Around 160 local employees, including SK Biopharm CEO Lee Dong Hoon, shared new goals and plans during this fifth annual sales meeting.
Cenobamate, known as Xcopri in the US, achieved sales of 270.8 billion won ($202.8 million) in the US market last year, representing a 60.1% increase compared to the previous year.
With a rapid increase in new patient prescriptions, the total number of prescriptions reached 26,000 in December last year.
SK Biopharm aims to achieve an annual sales target of $311 million for Cenobamate in the US this year and plans to increase total prescriptions (TRx) to over 30,000, aiming to become the leader in the prescription drug sector.
"Building on the profitable performance of the last quarter, this year will be the first year that we achieve full-year profitability and demonstrate the profitability of our business model of direct drug sales in the US," Lee said.
"With the accelerated growth of Cenobamate, we can introduce a second product through the local sales network."
Write to Dae-Kyu Ahn at powerzanic@hankyung.com
-
Bio & PharmaSK Biopharm, Dong-A ST sign licensing deal of Cenobamate
Jan 04, 2024 (Gmt+09:00)
1 Min read -
Bio & PharmaSK Biopharm gears up to boost epilepsy drug sales in Europe
Nov 16, 2023 (Gmt+09:00)
2 Min read -
Bio & PharmaSK Biopharma’s Cenobamate US patent extended by 2032
Nov 10, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaSK Biopharm to export epilepsy drug tech to Middle Eastern firm
Aug 18, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaSK Biopharmaceuticals forms Scientific Advisory Board
Aug 03, 2023 (Gmt+09:00)
1 Min read